Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from A US health plan perspective

Applied Health Economics and Health Policy

Volumn 11, Issue 3, 2013, Pages 299-304

  Joish, Vijay N ^a   Spilsbury Cantalupo, Monica ^a   Operschall, Elisabeth ^b   Luong, Ba ^b   Boklage, Susan ^a  

^a Bayer HealthCare Pharmaceuticals Inc   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; ECONOMIC BURDEN; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; NON CYSTIC FIBROSIS BRONCHIECTASIS; OUTPATIENT CARE; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRONCHIECTASIS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COMORBIDITY; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84878770088     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0027-z     Document Type: Article

References (15)

1. Evans DF, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. Cochrane Database Syst Rev. 2003;4:CD001392.
2. Ilowite J, Spiegler P, Chawala S. Bronchiectasis: new findings in the pathogenesis and treatment of this disease. Curr Opin Infect Dis. 2008;21(2):163-7.
3. Barker AF. Bronchiectasis. N Eng J Med. 2002;346(18):1383-93.
4. O'Donnell AE. Bronchiectasis. Chest. 2008;134(4):815-23.
5. Zoumot Z, Wilson R. Respiratory infection in noncystic fibrosis bronchiectasis. Curr Opin Infect Dis. 2010;23(2):165-70.
6. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565-72.
7. Prasad M, Tino G. Bronchiectasis, part 2: management. J Respir Dis. 2008;29(1):20-5.
8. Seitz AE, Olivier KN, Sreiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest. 2010;138(4):944-9.
9. Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12(4):205-9.
10. Metersky ML. New treatment options for bronchiectasis. Ther Adv Respir Dis. 2010;4(2):93-9.
11. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000-2007. Chest. 2012;142(2):432-9.
12. Patel IS, Vlahos I, Wilkinson TMA, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400-7.
13. O'Brian C, Guest PJ, Hill SL, et al. Physiological and radiological characterization of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55(8):635-42.
14. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140(5):1130-7.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-9.